Diagnosis and treatment of cognitive impairment in patients with chronic cerebral ischemia: The results of the observational Russian program diamant
Парфенов В. А., Живолупов С. А., Никулина К. В., Повереннова И. Е., Лапатюхин В. Г., Жестикова М. Г., Жукова Н. Г., Глазунов А. Б.
Журнал неврологии и психиатрии им. C.C. Корсакова
Т. 118, Вып. 6, С. 15-23
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.17116/jnevro20181186115
Аннотация:
Objective. To investigate the efficacy of divaza in outpatients with cognitive disorders and chronic brain ischemia (CBI). Material and methods. The non-interventional observational program included the data of 2583 outpatients with CBI from 30 cities (8 federal okrugs of the Russian Federation) who were on outpatient neurological treatment and received divaza in a dose of 2 tablets three times a day from Oct 2016 to Jan 2017. Cognitive functions were evaluated using the MoCA scale before and after 3 months of treatment. Results and conclusion. Cognitive disorders were identified in 90.7[%] of patients (<26 МоСА scores). After treatment, the mean MoCA score increased from 19.58 ± 5.13 to 23.99 ± 4.21 (p<0.0001), the number of patients with normal cognitive functions rate (≥26 scores) increased from 9.3 to 41.3[%], the number of patients with marked cognitive impairment decreased. The drug was well-tolerated by old and very old patients, adverse events were observed rarely (0.6[%] of cases).
Ключевые слова:
Divaza; Hypertension-associated microangiopathy; Mild cognitive impairment; MoCA test; Observational program
azacitidine; Article; brain ischemia; cognition; cognitive defect; drug efficacy; human; major clinical study; Montreal cognitive assessment; outpatient; cognitive defect; neuropsychological test; Russian Federation; Brain Ischemia; Cognition; Cognitive Dysfunction; Humans; Neuropsychological Tests; Russia
Язык текста: Русский
ISSN: 2309-4729
Парфенов В. А. Владимир Анатольевич 1957-
Живолупов С. А.
Никулина К. В.
Повереннова И. Е.
Лапатюхин В. Г.
Жестикова М. Г.
Жукова Н. Г.
Глазунов А. Б.
Parfenov V. A. Vladimir Anatolyevich 1957-
Zhivolupov S. A.
Nikulina K. V.
Poverennova I. E.
Lapatuhin V. G.
Zhestikova M. G.
Zhukova N. G.
Glazunov A. B.
Diagnosis and treatment of cognitive impairment in patients with chronic cerebral ischemia: The results of the observational Russian program diamant
Текст визуальный непосредственный
Журнал неврологии и психиатрии им. C.C. Корсакова
Издательство Медиа Сфера
Т. 118, Вып. 6 С. 15-23
2018
Статья
Divaza Hypertension-associated microangiopathy Mild cognitive impairment MoCA test Observational program
azacitidine Article brain ischemia cognition cognitive defect drug efficacy human major clinical study Montreal cognitive assessment outpatient cognitive defect neuropsychological test Russian Federation Brain Ischemia Cognition Cognitive Dysfunction Humans Neuropsychological Tests Russia
Objective. To investigate the efficacy of divaza in outpatients with cognitive disorders and chronic brain ischemia (CBI). Material and methods. The non-interventional observational program included the data of 2583 outpatients with CBI from 30 cities (8 federal okrugs of the Russian Federation) who were on outpatient neurological treatment and received divaza in a dose of 2 tablets three times a day from Oct 2016 to Jan 2017. Cognitive functions were evaluated using the MoCA scale before and after 3 months of treatment. Results and conclusion. Cognitive disorders were identified in 90.7[%] of patients (<26 МоСА scores). After treatment, the mean MoCA score increased from 19.58 ± 5.13 to 23.99 ± 4.21 (p<0.0001), the number of patients with normal cognitive functions rate (≥26 scores) increased from 9.3 to 41.3[%], the number of patients with marked cognitive impairment decreased. The drug was well-tolerated by old and very old patients, adverse events were observed rarely (0.6[%] of cases).